Compugen Reports Second Quarter 2018 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Compugen Reports Second Quarter 2018 Results

Compugen (CGEN) Reports In-Line Q2 EPS

August 1, 2018 7:09 AM EDT

Compugen (NASDAQ: CGEN) reported Q2 EPS of ($0.19), in-line with the analyst estimate of ($0.19).

"The first half of 2018 has been transformational for Compugen, and we are excited to soon dose the first patient in the Phase 1 clinical trials for COM701, our lead cancer immunotherapy program," said Anat Cohen-Dayag, Ph.D., President and CEO of Compugen. "COM701 is a first-in-class therapeutic antibody targeting PVRIG, a novel immune checkpoint originating from Compugen\'s computational discovery efforts. Based on the mechanistic rationale for this newly-discovered... More